Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.
|Articles|October 6, 2003
Cover Story: HIV--FROM DEATH SENTENCE TO CHRONIC DISEASE
New antivirals and updated guidelines offer opportunities for R.Ph. management of this drug-intensive disease
Advertisement
Advertisement
Related to this article
Harini Bupathi, Esq, explains why pharmacies need to continue prioritizing PBM relationships despite rapid legislative change.
Researchers assessed the extent of which vaccine fatigue translates to reduced engagement and adherence among patients.
Brianne Porter, PharmD, MS, explores how pharmacists can deliver care to a population of women experiencing life-altering symptoms of urinary incontinence.
AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.
Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
Q&A: Why Enforcement Is the Weak Link in State PBM Reform | NCPA 2026
3
Pharmacist Roles, Risks in Guiding AI-Enabled Medical Device Use
4
Vaccine Fatigue May Stall Patient Uptake More Than Hesitancy
5